Literature DB >> 19260120

The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.

Bradley A McGregor1, Alexander W Brown, Michael B Osswald, Michael R Savona.   

Abstract

The standard dose of clofarabine is 52 mg/m2 for pediatrics and 40 mg/m2 in adults. Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT. All patients had a significant response to therapy. Published pharmacokinetic analysis revealed no difference in peak plasma or intracellular concentrations at clofarabine dosed above 40 mg/m2, yet inhibition of replication in leukemia cells was only sustained over 24 hr at 55 mg/m2. Despite this, there have been no reports of high dose clofarabine used in this setting. Our experience implies that there may be a niche role for clofarabine in reducing disease burden before allo-HSCT for adults with relapsed ALL. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19260120     DOI: 10.1002/ajh.21365

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Authors:  Amer M Zeidan; Rebecca M Ricklis; Hetty E Carraway; Hyun D Yun; Jacqueline M Greer; B Douglas Smith; Mark J Levis; Michael A McDevitt; Keith W Pratz; Margaret M Showel; Douglas E Gladstone; Steven D Gore; Judith E Karp
Journal:  Br J Haematol       Date:  2012-05-18       Impact factor: 6.998

2.  Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia.

Authors:  Kotaro Arita; Takeshi Kondo; Junichi Sugita; Akio Shigematsu; Souichi Shiratori; Kentaro Wakasa; Atsushi Yasumoto; Makoto Ibata; Yusuke Shono; Misato Kikuchi; Hideki Goto; Yukari Takeda; Mutsumi Takahata; Naoko Kato; Mitsufumi Nishio; Shuichi Ota; Junji Tanaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2011-08-31       Impact factor: 2.490

3.  [18F] Clofarabine for PET Imaging of Hepatocellular Carcinoma.

Authors:  Olga Sergeeva; Vladimir Kepe; Yifan Zhang; Galen A Miller-Atkins; Jonathan D Keynon; Renuka Iyer; Sandra Sexton; Amad Awadallah; Wei Xin; Yogen Saunthararajah; E Ricky Chan; Zhenghong Lee
Journal:  Cancers (Basel)       Date:  2019-11-07       Impact factor: 6.639

Review 4.  Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents.

Authors:  Gordon M Cragg; John M Pezzuto
Journal:  Med Princ Pract       Date:  2015-12-17       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.